These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 18957471)
1. HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Lange RA; Lindsey ML Eur Heart J; 2008 Nov; 29(22):2708-9. PubMed ID: 18957471 [No Abstract] [Full Text] [Related]
2. New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol. Harv Heart Lett; 2007 Mar; 17(7):1-2. PubMed ID: 17378073 [No Abstract] [Full Text] [Related]
3. Illuminating HDL--is it still a viable therapeutic target? Rader DJ N Engl J Med; 2007 Nov; 357(21):2180-3. PubMed ID: 17984168 [No Abstract] [Full Text] [Related]
4. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit. Taylor J Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754 [No Abstract] [Full Text] [Related]
6. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors? Miura S; Saku K J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856 [No Abstract] [Full Text] [Related]
8. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case. Barter PJ; Nicholls SJ; Kastelein JJ; Rye KA Circulation; 2015 Aug; 132(5):423-32. PubMed ID: 26240263 [No Abstract] [Full Text] [Related]
9. Where now for new drugs for atherosclerosis? Opar A Nat Rev Drug Discov; 2007 May; 6(5):334-5. PubMed ID: 17539053 [No Abstract] [Full Text] [Related]
10. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief? Hovingh GK; Ray KK; Boekholdt SM Circulation; 2015 Aug; 132(5):433-40. PubMed ID: 26240264 [No Abstract] [Full Text] [Related]
11. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435 [No Abstract] [Full Text] [Related]
12. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream? Ahmed MH Diabetes Technol Ther; 2008 Aug; 10(4):328-9. PubMed ID: 18715207 [No Abstract] [Full Text] [Related]
14. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Oram JF; Heinecke JW Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780 [No Abstract] [Full Text] [Related]
15. CETP inhibitors to increase HDL cholesterol levels. Tall AR N Engl J Med; 2007 Mar; 356(13):1364-6. PubMed ID: 17387130 [No Abstract] [Full Text] [Related]
16. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
18. From the editor: selling the benefit of drug therapy. Brown WV J Clin Lipidol; 2013; 7(1):1-2. PubMed ID: 23351576 [No Abstract] [Full Text] [Related]
19. HDL- cholesterol: a nut too hard to crack? Kaski JC Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352 [No Abstract] [Full Text] [Related]
20. Refocusing on use of cholesteryl ester transfer protein inhibitors. Kastelein JJ Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]